The incidence of tuberculosis recurrence: Impacts of treatment duration of and adherence to standard anti-tuberculous therapy

被引:1
作者
Lee, Chung-Shu [1 ,2 ]
Ho, Chung-Han [3 ,4 ,5 ]
Liao, Kuang-Ming [6 ]
Wu, Yu-Cih [3 ]
Shu, Chin-Chung [7 ,8 ]
机构
[1] New Taipei Municipal TuCheng Hosp, Dept Pulm & Crit Care Med, New Taipei City, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp, Sch Med, Dept Thorac Med, Taipei, Taiwan
[3] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan
[4] Southern Taiwan Univ Sci & Technol, Dept Informat Management, Tainan, Taiwan
[5] Taipei Med Univ, Taipei Municipal Wanfang Hosp, Canc Ctr, Taipei, Taiwan
[6] Chi Mei Med Ctr, Dept Internal Med, Chiali, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[8] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
关键词
Complete adherence; TB recurrence; Treatment duration; Tuberculosis; PREVENTION/INFECTIOUS DISEASES SOCIETY; AMERICAN THORACIC SOCIETY/CENTERS; PRACTICE GUIDELINES TREATMENT; DRUG-RESISTANCE; REGIMENS;
D O I
10.1016/j.jiph.2023.09.005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: We investigated the impacts of the standard treatment durations of and adherence to standard anti-tuberculous therapy (ATT) on recurrence after the successful completion of tuberculosis (TB) treatment.Methods: We recruited patients with TB who had received treatment for six or nine months from the 2008-2017 databases of the Taiwanese National Health Insurance Research Database. Treatment duration and adherence to standard ATT were analyzed for their impacts on recurrence within two years. Complete adherence to standard ATT was defined as daily use of ethambutol, isoniazid, pyrazinamide, and rifampin for the first two months, and daily use of isoniazid and rifampin for the first six months.Results: A total of 33,298 TB patients with new-onset TB were identified and classified into two groups by treatment duration: six months (n = 25,849, 77.63%) and nine months (n = 7449). Sex and age distributions varied between the groups. Treatment duration did not affect TB recurrence within two years (adjusted hazard ratio (AHR): 1.18, 95% confidence interval (C.I.) [0.96-1.4 4], p = 0.1156). Multivariable logistic regression showed that incomplete adherence to standard anti-tuberculous therapy (80-89% and 90-99% standard anti-TB therapy, AHR: 1.57, 95% C.I. [1.26-1.95], and 1.63, 95% C.I. [1.26-2.06], respectively, p < 0.0001) increased TB recurrence. In addition, male sex, older age, and comorbidity with diabetes mellitus or chronic obstructive pulmonary disease were independent risk factors for TB recurrence within two years.Conclusions: TB recurrence was 1.54% within two years under a DOT era. TB treatment durations of six or nine months did not affect TB recurrence within two years after completion of TB treatment, but incomplete adherence to standard anti-tuberculous therapy might increase the TB recurrence rate.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/li-censes/by-nc-nd/4.0/).
引用
收藏
页码:1778 / 1783
页数:6
相关论文
共 33 条
  • [1] [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
  • [2] Recurrence of tuberculosis among patients following treatment completion in eight provinces of Vietnam: A nested case-control study
    Bestrashniy, Jessica Rutledge Bruce Musselman
    Nguyen Viet Nhung
    Nguyen Thi Loi
    Pham Thi Lieu
    Nguyen Thu Anh
    Pham Duc Cuong
    Nghiem Le Phuong Hoa
    Le Thi Ngoc Anh
    Nguyen Binh Hoa
    Nguyen Kim Cuong
    Nguyen Huy Dung
    Tran Ngoc Buu
    Le Thi Nhung
    Nguyen Viet Hung
    Dinh Ngoc Sy
    Britton, Warwick John
    Marks, Guy Barrington
    Fox, Greg James
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 74 : 31 - 37
  • [3] Centers for Disease Control MoHaW R.O.C.(Taiwan), 2022, Taiwan guidelines for TB diangosis and treatment, V5th
  • [4] Improved Consistency in Dosing Anti-Tuberculosis Drugs in Taipei, Taiwan
    Chiang, Chen-Yuan
    Yu, Ming-Chih
    Shih, Hsiu-Chen
    Yen, Muh-Yong
    Hsu, Yu-Ling
    Yang, Shiang-Lin
    Lin, Tao-Ping
    Bai, Kuan-Jen
    [J]. PLOS ONE, 2012, 7 (08):
  • [5] Tuberculosis recurrence and mortality after successful treatment:: Impact of drug resistance
    Cox, Helen
    Kebede, Yared
    Allamuratova, Sholpan
    Ismailov, Gabit
    Davletmuratova, Zamira
    Byrnes, Graham
    Stone, Christine
    Niemann, Stefan
    Ruesch-Gerdes, Sabine
    Blok, Lucie
    Doshetov, Daribay
    [J]. PLOS MEDICINE, 2006, 3 (10) : 1836 - 1843
  • [6] Long term efficacy of DOTS regimens for tuberculosis: systematic review
    Cox, Helen S.
    Morrow, Martha
    Deutschmann, Peter W.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7642): : 484 - 487
  • [7] Recurrent tuberculosis in the Netherlands - a 24-year follow-up study, 1993 to 2016
    Erkens, Connie
    Tekeli, Betul
    van Soolingen, Dick
    Schimmel, Henrieke
    Verver, Suzanne
    [J]. EUROSURVEILLANCE, 2022, 27 (12)
  • [8] Executive B, 2014, Global strategy and targets for tuberculosis prevention, care and control after 2015: Report by the Secretariat
  • [9] Recurrent Tuberculosis Disease in Singapore
    Gan, Suay Hong
    KhinMar, Kyi Win
    Ang, Li Wei
    Lim, Leo K. Y.
    Sng, Li Hwei
    Wang, Yee Tang
    Chee, Cynthia B. E.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):
  • [10] Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
    Gillespie, Stephen H.
    Crook, Angela M.
    McHugh, Timothy D.
    Mendel, Carl M.
    Meredith, Sarah K.
    Murray, Stephen R.
    Pappas, Frances
    Phillips, Patrick P. J.
    Nunn, Andrew J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17) : 1577 - 1587